Apoptosis
The number of cells in multicellular organism is tightly regulated. Not simply by controlling the rate of cell division, but also by controlling the rate of cell death. If cells are no longer needed, they commit suicide by activating an intracellular death program. This process is therefore called programmed cell death or apoptosis (from a Greek word meaning “falling off,” as leaves from a tree). The intrinsic apoptotic pathway occurs by the release of cytochrome c from mitochondria. The extrinsic apoptotic pathway is caused by the binding of death ligands, such as TNF (tumor necrosis factor), Fas, and TRAIL (TNF-related-apoptosis-inducing ligand), to their corresponding receptors. Although programmed cell death is involved in a number of key biological phenomena, aberrant apoptosis results in diverse human diseases [1].
The amount of apoptosis that occurs in developing and adult animal tissues is surprisingly large. In the developing vertebrate nervous system up to half or more of the nerve cells normally die soon after they are formed. In a healthy adult human, billions of cells die in the bone marrow and intestine every hour. Although this process seems remarkably wasteful -especially as the vast majority are perfectly healthy at the time they kill themselves- programmed cell death plays an important role during embryonic development, as hands and feet, for example, are sculpted by apoptosis: they start out as spadelike structures, and the individual digits separate only as the cells between them die. In other cases, cells die when the structure they form is no longer needed. When a tadpole changes into a frog, the cells in the tail die, and the tail, which is not needed in the frog, disappears. In many other cases, cell death helps regulate cell numbers. In the developing nervous system, for example, cell death adjusts the number of nerve cells to match the number of target cells that require innervation. In all these cases, the cells die by apoptosis as well[2].
[2] D.R. Williams et al. An apoptosis-inducing small molecule that binds to heat shock protein 70. Angew. Chem. Int. Ed. Engl. 2008, 47, 7466-7469.
[1] B. Alberts, A. Johnson, J. Lewis et al. Molecular Biology of the Cell. 4th edition. New York. Garland Science, 2002.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
3039 | ACY-241 | Selective and orally available HDAC6 inhibitor | €120.00 | |
2269 | AK 1 | Potent inhibitor of SIRT with good selectivity for SIRT2 over SIRT1 and SIRT3 | €90.00 | |
2270 | AK 7 | Potent, brain-permeable and selective inhibitor of SIRT2 | €90.00 | |
2394 | AR-42 | HDAC inhibitor | €125.00 | |
5052 | Axon Ligands™ Epigenetic compound library | Axon Ligands™ Epigenetic compound library | Inquire | |
2635 | BAY-598 | Selective inhibitor of SMYD2 | €110.00 | |
2735 | BCI-121 | Inhibitor of SMYD3 | €90.00 | |
3115 | Belinostat | HDAC inhibitor | €70.00 | |
3397 | BG45 | HDAC inhibitor (1, 2, 3 Selective) | €80.00 | |
1692 | BIX 01294 trihydrochloride | HMTase inhibitor (G9a and G9a-like protein) | €80.00 | |
3399 | BML-210 | HDAC inhibitor | €80.00 | |
2471 | BRD 73954 | Dual HDAC 6/8 inhibitor with excellent selectivity over the other HDACs | €85.00 | |
2803 | Cambinol | Inhibitor of SIRT1 and SIRT2 | €95.00 | |
2250 | CHR 6494 trifluoroacetate | Specific, first-in-class inhibitor of histone kinase Haspin | €120.00 | |
2014 | CI 994 | HDAC inhibitor that causes histone hyperacetylation in living cells | €70.00 | |
2812 | CM-272 | First-in-class potent, selective and reversible inhibitor of G9a/DNMT | €130.00 | |
2594 | CPI 0610 | Selective and metabolically stable inhibitor of BET bromodomains | Inquire | |
3038 | CXD101 | HDAC inhibitor (1, 2, 3 Selective) | €125.00 | |
2227 | EPZ 6438 | Inhibitor of Histone Lysine Methyltransferase EZH2 | €80.00 | |
4137 | EPZ005687 hydrochloride | EZH2 HMTase inhibitor | Inquire | |
2140 | GSK 126 | Inhibitor of Histone Lysine Methyltransferase EZH2 | €75.00 | |
1645 | HDAC6 inhibitor ISOX | HDAC6 Inhibitor | €110.00 | |
2529 | JNJ 26481585 dihydrochloride | Potent, orally available second-generation pan-HDAC inhibitor | €125.00 | |
1548 | LBH 589 | HDAC1 Inhibitor | €90.00 | |
2430 | LW 479 | HDAC inhibitor with cytotoxicity in a panel of breast cancer cell lines. | €135.00 | |
1707 | MC 1568 | HDAC inhibitor (class IIA selective) | €85.00 | |
2505 | Mocetinostat | Class I selective HDAC inhibitor with broad spectrum antitumor activity | €80.00 | |
1803 | MS 275 | Inhibitor of HDAC (1 and 3 Selective) | €60.00 | |
3469 | MS1943 trifluoroacetate | First-in-class EZH2 selective degrader; PROTAC | €200.00 | |
2359 | Nexturastat A | HDAC6 inhibitor with good selectivity over HDAC1 and HDAC8 | €90.00 |